Enrica Marchi, MD PhD

Dr. Enrica Marchi is an Assistant Professor of Medicine with an appointment to the Division of Hematology/Oncology, Department of Medicine at the NCI-Designated Cancer Center of the University of Virginia, in Charlottesville, VA.
Dr. Marchi obtained her Medical Doctorate and completed her training in hematology in Italy, and then she completed her PhD in clinical and experimental hematology and hematopathology focusing her research largely on the translational development of novel rational drug combinations for patients with peripheral T-cell lymphoma (PTCL). Dr.Marchi leads the T-cell lymphoid malignancies clinical research program and CTCL multidisciplinary clinic at UVA along with the portfolio of sponsored initiated trials including IIT and industry-sponsored trials. She is regarded as one of the experts in the field of T-cell lymphoma and she regularly is invited to present at national and international meetings.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:MerckTopic:Research FundingDate added:01/22/2025Date updated:01/22/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:Bristol Myers SquibbTopic:Research FundingDate added:01/22/2025Date updated:01/22/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:Dren BioTopic:Research FundingDate added:01/22/2025Date updated:01/22/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:Kymera TherapeuticsTopic:Research FundingDate added:01/22/2025Date updated:01/22/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:Kyowa KirinTopic:Scientific AdvisorDate added:01/22/2025Date updated:01/22/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:Vittoria BiotherapeuticsTopic:Scientific AdvisorDate added:01/22/2025Date updated:01/22/2025
-
Attribution:SelfType of financial relationship:OtherIneligible company:AcrotechTopic:Scientific AdvisorDate added:01/22/2025Date updated:01/22/2025